Revvity, Inc. Hits Day High with Strong 7.36% Intraday Surge

Revvity, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable surge today, gaining 7.36% and reaching an intraday high of USD 99.93. This performance stands in stark contrast to the S&P 500, which has only seen a 1.46% increase on the same day. Over the past week, Revvity has shown a robust performance with a 20.46% increase, while its one-month performance is up by 12.19%. However, the company has faced challenges in the long term, with a five-year annual growth rate in net sales of -1.23% and operating profit declining at -2.67%. The return on capital employed (ROCE) is currently at a low 10.24%, indicating limited profitability relative to total capital. Despite the recent uptick, Revvity's year-to-date performance remains modest at 2.42%, and it has underperformed the S&P 500 over the last three years. The company's market capitalization stands at USD 9,668 million, with a price-to-earnings ratio of 34.00 and a dividend yield of 0.34%.